1h Free Analyst Time
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2022, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Phase III, Phase II and Phase I stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Alcohol Addiction, Major Depressive Disorder and Psychiatric Disorders.
Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
Ctcbio Inc
Sobrera Pharma AB
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDFF-0318 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cytisinicline - Drug Profile
Product Description
Mechanism Of Action
History of Events
ropanicant [INN] - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News
Apr 27, 2022: Achieve Life Sciences announces successful, statistically significant smoking cessation results in phase 3 ORCA-2 clinical trial of cytisinicline in adult smokers
Jan 25, 2022: Achieve Life Sciences announces initiation of the phase 3 ORCA-3 clinical trial evaluating cytisinicline for smoking cessation
Jan 04, 2022: Achieve Life Sciences announces completion of last subject, last follow-up visit in phase 3 ORCA-2 trial of cytisinicline for smoking cessation
Dec 22, 2021: Achieve Life Sciences announces $25 million loan facility from Silicon Valley Bank to fund cytisinicline smoking cessation clinical development
Nov 22, 2021: Achieve Life Sciences announces phase 3 ORCA-2 trial of cytisinicline in smoking cessation clears final review by Data Safety Monitoring Committee (DSMC)
Nov 02, 2021: Achieve Life Sciences announces FDA acceptance of IND application for Cytisinicline’s second planned indication for nicotine E-cigarette cessation
Oct 14, 2021: Class 2 Medicines Recall: Pfizer Ltd, Champix (all strengths) film-coated tablets
Sep 20, 2021: Health Canada approves COVID-19 vaccine brand name Comirnaty
Sep 16, 2021: Pfizer expands voluntary nationwide recall to include all lots of CHANTIX (varenicline) tablets due to N-Nitroso Varenicline Content
Sep 14, 2021: Achieve Life Sciences announces presentation of Cytisinicline data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
Aug 13, 2021: Pfizer expands voluntary nationwide recall to include four additional lots of CHANTIX (varenicline) tablets due to NNitroso Varenicline content
Aug 13, 2021: Achieve Life Sciences announces expansion of Cytisinicline clinical operations team and granting of inducement awards
Aug 11, 2021: Achieve announces two patents granted by USPTO for novel Cytisinicline dosing and administration regimen
Aug 05, 2021: Therapeutic Goods Administration provides update on Varenicline
Jul 22, 2021: Achieve Life Sciences awarded grant from the National Institutes of Health (NIH) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development by Stage of Development, 2022
- Number of - Products under Development by Therapy Areas, 2022
- Number of - Products under Development by Indication, 2022
- Number of - Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Ctcbio Inc, 2022
- Pipeline by Sobrera Pharma AB, 2022
- Pipeline by Sopharma AD, 2022
- Pipeline by Suven Life Sciences Ltd, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
List of Figures
- Number of - Products under Development by Stage of Development, 2022
- Number of - Products under Development by Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ctcbio Inc
- Sobrera Pharma AB
- Sopharma AD
- Suven Life Sciences Ltd
